Equities Analysts Set Expectations for SRTS FY2024 Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Analysts at Roth Capital increased their FY2024 EPS estimates for Sensus Healthcare in a research note issued to investors on Thursday, November 14th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $0.40 per share for the year, up from their prior forecast of $0.36. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.09 EPS, Q1 2025 earnings at $0.16 EPS and Q2 2025 earnings at $0.19 EPS.

A number of other research firms have also recently weighed in on SRTS. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a report on Monday, August 12th. Maxim Group lifted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday.

Sensus Healthcare Stock Up 4.8 %

NASDAQ SRTS opened at $7.64 on Monday. Sensus Healthcare has a 52 week low of $2.02 and a 52 week high of $8.29. The business’s fifty day simple moving average is $6.37 and its 200-day simple moving average is $5.95. The firm has a market cap of $125.22 million, a PE ratio of 13.40 and a beta of 1.04.

Institutional Trading of Sensus Healthcare

Institutional investors and hedge funds have recently modified their holdings of the business. Truvestments Capital LLC purchased a new position in shares of Sensus Healthcare during the 3rd quarter worth $32,000. Chapin Davis Inc. acquired a new stake in Sensus Healthcare in the 2nd quarter worth about $53,000. XTX Topco Ltd purchased a new stake in Sensus Healthcare in the 2nd quarter valued at about $95,000. Hillsdale Investment Management Inc. acquired a new position in shares of Sensus Healthcare during the 1st quarter valued at about $155,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth about $156,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.